Professor Ravindra Gupta is member of AHRI Faculty and a Professor in University College London’s (UCL) Division of Infection & Immunity. He initially trained as a clinical infectious diseases physician and went on to do a PhD at UCL, where he examined the epidemiology and virology of HIV drug resistance in sub Saharan Africa and the interplay between the restriction factor tetherin and the HIV gene Vpu. Most of his work since has focussed on antiviral therapy for treatment of HIV, and he has led a number of studies, both clinical and in vitro, aimed at addressing the global emerging threat of drug resistant HIV. Ravi also leads an active basic lab science programme at UCL, working on the cellular biology of retroviruses. This work complements his research into drug resistance by expanding our knowledge of how viruses manipulate the host environment in order to persist; this will inevitably impact response to drugs and the search for a cure. His programme of work is informed by clinical work as an infectious diseases physician in London where he has been able to study unique individuals with HIV in order to better understand viral reservoirs and immune control of HIV. Excitingly, he is currently conducting a study in collaboration with Imperial College aiming to demonstrate the world’s second HIV cure by stem cell transplantation.
Get in touch with Ravi via firstname.lastname@example.org
Click here for a full list of publications.
Prof Ravi Gupta has had continuous Wellcome funding as a fellow since 2007, and most recently secured a Wellcome Senior Fellowship in 2016 to study the biological properties of drug resistant viruses in South Africa, including acquisition of increased replication fitness and cellular tropism changes as part of evolutionary adaptation to drug pressure. Africa Health Research Institute represents an ideal environment in which to study drug resistant HIV-1, given the large numbers of treated patients and the fact that 10% or more patients experience treatment failure. This project will bring together the multiple strands of his ongoing research to address critically important consequences of global access to antiretroviral therapy. Future plans include work on the role of myeloid cells in HIV associated brain disease during antiretroviral therapy, paving the way to study drug resistant reservoirs in the brain.
Meet the Team
Anne received her PhD from Paris VI University. She researched HIV resistance to ARVs in Mali, a setting where free access to HIV treatment was starting. After three years of postdoctoral studies at Stanford University, Anne joined the Africa Centre for Population Health in 2014 to evaluate how resistance may impact the reduction of HIV transmission in the Treatment as Prevention trial. At AHRI, her research is focussed more on the molecular mechanisms of HIV resistance.
Collaborating Research Fellow
Dami is a physician specialising in Infectious Diseases and a Wellcome Clinical PhD student at University College London. At AHRI Dami facilitates the HERB (HIV escape and resistance in the brain) study, which aims to investigate the occurrence of independent replication of HIV in the brain of South African patients with neurocognitive impairment and to study the evolution of drug resistance in these compartmentalised viruses.
Research Laboratory Technician
Camille completed her honours degree in Biochemistry at the University of KwaZulu-Natal. She joined the Gupta Group as an intern in 2017, and now holds the position of Research Laboratory Technician. She works on HIV drug resistance.
Selected Recent Publications
Mlcochova P, Sutherland KA, Watters SA, Bertoli C, de Bruin RAM, Rehwinkel J, Neil SJ, Lenzi GM, Kim B, Khwaja A, Gage MC, Georgiou C, Chittka A, Yona S, Noursadeghi M, Towers GJ, Gupta RK. (2017). A G1–like state allows HIV–1 to bypass SAMHD1 restriction in macrophages. EMBO J 2017; Mar 1;36(5):604-616.
Collier DA, Iwuji C, Derache A, de Oliveira T, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK for the ANRS 12249 TasP Study Group. (2017). Virological Outcomes of second–line protease inhibitor based treatment for HIV– 1 in a high prevalence rural South African setting – a competing risk prospective cohort analysis. Clinical Infectious Diseases; doi: 10.1093/cid/cix015; E pub ahead of print.
Sutherland KA, Collier DA, Claiborne DT, Prince JL, Deymier MJ, Goldstein RA, Hunter E, Gupta RK. (2016). Wide variation in susceptibility of HIV–1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency. Scientific Reports; 6: 38153 doi: 10.1038/srep38153 .
Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, Kanki P, Hoffmann CJ, Lockman S, Pillay D, de Oliveira T, Clumeck N, Hunt G, Kerschberger B, Shafer RW, Yang C, Raizes E, Kantor R, Gupta RK. (2017). Occult drug resistance to thymidine analogues and multidrug resistant HIV–1 following failure of first line tenofovir–based antiretroviral regimens in sub Saharan Africa: a retrospective multi–centre cohort study. Lancet Infect Dis Epub ahead of print: http://dx.doi.org/10.1016/S1473– 3099(16)30469– 8.
Gregson J, Tang M, Ndembi N, Hamers RL, Rhee SY, Marconi VC, Diero L, Brooks K, Theys, K, Rinke de Wit TF, Arruda M, Garcia F, Monge S, Günthard, HF, Hoffmann, CJ, Kanki PJ, Kumarasamy, N, Kerschberger B, Mor O, Charpentier C, Todesco E, Rokx C, Gras L, Halvas EK, Sunpath H, Di Carlo D, Antinori A, Andreoni M, Latini A, Mussini C, Aghokeng A, Sonnerborg A, Ujjwal Neogi U, Fessel WJ, Agolory S, Yang C, Blanco JL, Juma JM, Smit, E, Schmidt, D, Watera C, Asio J, Kirungi W, Tostevin A, El– Hay T, Clumeck N, Goedhals D; van Vuuren C, Bester PA, Sabin C, Mukui I, Santoro MM, Perno CF, Hunt G, Morris L, Camacho R, de Oliveira T, Pillay D, Schulter E, Akio Murakami– Ogasawara A, Reyes– Terán G, Romero K, Avila– Rios S, Sirivichayakul, S, Ruxrungtham K, Mekprasan S, Dunn, D, Kaleebu, P, Raizes E, Kantor R, Shafer RW, Gupta RK on behalf of the TenoRes study group. (2016). Global epidemiology of drug resistance following failure of WHO recommended first line regimens for adult HIV–1 infection – a multi–centre retrospective cohort study. Lancet Infect Dis 2016. May;16(5):565– 75.